The first-time admissions to hospices from 2000–2006, stratified by patient’s residence and hospice’s location.

<p>The first-time admissions to hospices from 2000–2006, stratified by patient’s residence and hospice’s location.</p

Additional file 1 of Role of nebulized colistin as a substitutive strategy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective cohort study

Additional file 1. Materials and methods

Hospice resources and utilization from 2000–2006.

<p>Hospice resources and utilization from 2000–2006.</p

Features of cancer patients with hospice care during 2000–2006, stratified by location of residence.

<p>Features of cancer patients with hospice care during 2000–2006, stratified by location of residence.</p

Urban-rural disparities of cancer patients with first-time hospice care from 2000–2006.

<p>Urban-rural disparities of cancer patients with first-time hospice care from 2000–2006.</p

DataSheet_1_Circulating mitochondrial cell-free DNA dynamics in patients with mycobacterial pulmonary infections: Potential for a novel biomarker of disease.doc

ObjectivesHuman mitochondrial cell-free DNA (Mt-cfDNA) may serve as a useful biomarker for infectious processes. We investigated Mt-cfDNA dynamics in patients with pulmonary mycobacterial infections to determine if this novel biomarker could be used to differentiate disease states and severity.MethodsPatients with pulmonary tuberculosis (PTB), latent tuberculosis infection (LTBI), and nontuberculous mycobacterial-lung disease (NTM-LD) were enrolled at a tertiary care hospital in Taiwan between June 2018 and August 2021. Human Mt-cfDNA and nuclear-cfDNA (Nu-cfDNA) copy numbers were estimated by quantitative polymerase chain reaction. Variables associated with PTB and 2-month sputum culture-positivity, indicating poor treatment response, were assessed using logistic regression.ResultsAmong 97 patients with PTB, 64 with LTBI, and 51 with NTM-LD, Mt-cfDNA levels were higher in patients with PTB than in LTBI (p=0.001) or NTM-LD (p=0.006). In the Mycobacterium tuberculosis-infected population, Mt-cfDNA levels were highest in smear-positive PTB patients, followed by smear-negative PTB (p6 copies/μL-plasma was associated with a 10-fold risk of 2-month culture-positivity (adjusted OR 9.691 [1.046–89.813], p=0.046).ConclusionElevated Mt-cfDNA levels were associated with PTB disease and failed sputum conversion at 2 months in PTB patients, and decreased after treatment.</p

Additional file 1 of Engineered extracellular vesicles carrying let-7a-5p for alleviating inflammation in acute lung injury

Additional file 1: Figure S1. Validation of MSC surface markers and their differentiation ability. Figure S2. Characterization of the exosomal surface markers of EVs via ExoView. Figure S3. RNA content determined by qRT-PCR. Figure S4. EV uptake by lung-originated cell lines. Table S1. The total concentration, mean, and mode size of EVs from three batches. Table S2. Predicted lung fibrosis-related targets of let-7a-5p. Table S3. Top 20 let-7a-5p mediated pathways analyzed via CPDB